Migdal Insurance & Financial Holdings Ltd. Buys 300,000 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Migdal Insurance & Financial Holdings Ltd. increased its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 1.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,335,422 shares of the company's stock after purchasing an additional 300,000 shares during the period. Teva Pharmaceutical Industries makes up approximately 5.7% of Migdal Insurance & Financial Holdings Ltd.'s holdings, making the stock its biggest position. Migdal Insurance & Financial Holdings Ltd. owned 2.32% of Teva Pharmaceutical Industries worth $404,775,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of TEVA. Thrivent Financial for Lutherans raised its position in Teva Pharmaceutical Industries by 0.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock worth $4,964,000 after buying an additional 699 shares during the last quarter. Bfsg LLC increased its position in shares of Teva Pharmaceutical Industries by 7.8% during the 1st quarter. Bfsg LLC now owns 10,960 shares of the company's stock valued at $168,000 after purchasing an additional 790 shares during the last quarter. Townsquare Capital LLC increased its position in shares of Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock valued at $885,000 after purchasing an additional 812 shares during the last quarter. Quadrant Capital Group LLC increased its position in shares of Teva Pharmaceutical Industries by 27.7% during the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after purchasing an additional 949 shares during the last quarter. Finally, Blair William & Co. IL increased its position in shares of Teva Pharmaceutical Industries by 9.4% during the 4th quarter. Blair William & Co. IL now owns 11,232 shares of the company's stock valued at $248,000 after purchasing an additional 963 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the business's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the transaction, the executive vice president owned 9,989 shares of the company's stock, valued at approximately $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.49% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on TEVA. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Truist Financial began coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price target for the company. The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a "buy" rating and a $24.00 target price for the company. Bank of America increased their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Finally, JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. One analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $24.71.

Teva Pharmaceutical Industries Stock Performance

TEVA stock traded up $0.24 during trading on Monday, hitting $16.30. 8,210,997 shares of the company traded hands, compared to its average volume of 10,328,015. The stock's 50-day simple moving average is $16.98 and its 200 day simple moving average is $16.87. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74. The company has a market cap of $18.69 billion, a PE ratio of -14.17, a P/E/G ratio of 0.94 and a beta of 0.60. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. The business had revenue of $3.89 billion during the quarter, compared to analysts' expectations of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The business's revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.48 earnings per share. On average, equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.